Ascentage Pharma Group International (NASDAQ:AAPG) Coverage Initiated by Analysts at Citigroup

Equities researchers at Citigroup began coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $46.00 price target on the stock. Citigroup’s price target points to a potential upside of 213.14% from the company’s current price.

Other analysts have also recently issued research reports about the company. Citizens Jmp started coverage on Ascentage Pharma Group International in a report on Tuesday. They set a “market outperform” rating and a $35.00 price objective on the stock. William Blair initiated coverage on Ascentage Pharma Group International in a research report on Friday. They set an “outperform” rating for the company. JPMorgan Chase & Co. decreased their price objective on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a report on Thursday, October 8th. Finally, BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Three equities research analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $43.90.

Ascentage Pharma Group International Trading Down 1.1%

Shares of NASDAQ:AAPG opened at $14.69 on Wednesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The business has a fifty day moving average price of $16.55 and a two-hundred day moving average price of $19.11. Ascentage Pharma Group International has a 1 year low of $14.45 and a 1 year high of $37.50.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million during the quarter. Sell-side analysts anticipate that Ascentage Pharma Group International will post -2.42 EPS for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.